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864 Cardiac Function: Gene Transfer 
Tuesday, April 01, 2003,4:00 p.m.-500 p.m. 
Background: We sought to investigate the effect of systolic, diastolic or systolic and dias- 
tolic (combined) blood pressure response to exercise on left ventricular (LV) mass and 
McCorthck~Place, Room S402 
geometry in a group of patients undergoing stress echocardiography. 
4:oo pm 
Methods: Eight hundred and fifty nine consecutive patients with non-elevated restmg 
blood pressure (<140/90 mmHg) and no significant valvular or congenital disease who 
864_1 
Gene Transfer of Contractilin, a Recombinant lnotropic 
- 
underwent stress echocardiography, were studled. Hypertensive response to exercise Antibody-Based Protein, Improves Cardiac Function in 
(HTNRE) was defined as a peak exercise systolic blood pressure z.200 mmHg and/or a the BIO 14.6 Hamster 
diastolic blood pressure >SOmmHg. Patients were grouped according to 4 LV geometric 
patterns: normal, concentric remodeling (CR), concentric hyperirophy (cLVH) and eccen- 
Thomas Dieterle Markus Meyer, Yusu Gu. Hlroshl Ashikaga, Eric Swanson, Mitsuo ’ 
tric hypertrophy (eLVH) 
Iwatate, Kirk L. Peterson, Wolfgang H. Dillmann, John Ross, Jr., University of California, 
San Diego, La Jolla, CA 
Results: HTNRE was present an 234 (27.2%) patients. There were 39 pabents (16.7%) Background: Contractilin, a novel recombinant antibody-based protein, mimicks phos- 
with systolic HTNRE, 164 (70.1%) with diastolic HTNRE, and 31 (13.2%) with a coin- phorylation of phospholamban when expressed in cardiac myocytes. Using a high eff- 
bmed HTNRE. An abnormal LV geometry was found in 60% of patients with a normoten- c~ency in viva gene transfer (GT) method we investigated whether contractilin can 
save response to exercise, in 77% of patients with systolic HTNRE, in 74% of patients improve cardiac function in an animal model of established heart failure, the 810 14.6 
with diastolic HTNRE and in 90% of pattents with combined HTNRE (pcO.001) cardiomyopathic (CM) hamster. 
Type of response LV geometry (p<O.OOl) 
Normal CR e-LVH c-LVH Total 
Normotensive 247 (39.5) 262 (41.9) 34 (5.4) 62 (13.1) 625 
Methods: GT was performed in 12-14 week old CM hamsters as previously described 
(Ikeda Y et al, Circulation 105: 502.508, 2002) using intracoronary delivery of adenovirus 
containing the contractilin or thep-galactosidase (LacZ) gene (titer8xlOE9 PFU each). A 
third group was injected with saline (Sham). Echocardiography was performed before 
and 4-5 days after GT (D415). Hemodynamic parameters were measured at D415 using 
left ventricular (LV) catheter-tip micromanometry. 
Results: Gene expression (LacZ) was 54+15% with a scattered pattern throughout the 
Systolic HTNRE 
Diastolic HTNRE 
Combined HTNRE 
9 (23.1) 
43 (26.2) 
3 (9.7) 
21 (53.8) 
77(47.0) 
15 (48.4) 
2 (5.1) 7 (17.9) 39 heart. Echocardiographic and hemodynamic results (mean&EM): 
13 (7.9) 31 (18.9) 164 
5 (16.1) 8 (25.8) 31 Contractilin (n=8) Laci! (n=8) Sham (n=8) 
Conclusion: Marked differences ware observed in LV mass and geometry in patients 
with and wtthout HTNRE. Diastolic is the most comnwn form of HTNRE to exercise. 
Diastolic or systolic HTNRE appear to be equally important based on their effect on LV 
mass and geometry. A combined HTNRE is almost always associated with an abnormal 
LV structure. 
Echocardiography 
FS (%) 
1209-64 Six-Minute Walk Test and Mortality in Patients With 
Heart Failure 
VCF (cl&) 
Jeptha P. Curtis, Saif S. Rathore, Yongfei Wang, Harlan M. Krumholz, Yale University Hemodynamics 
School of Medicine, New Haven, CT HR (l/min) 
Background: Poor 6.minute walk test (GMWT) performance (unable to walk, distance 
<300m) is believed to predict adverse outcomes in heart failure (HF) patients. We sought 
to confirm the utility of these cutpoints and evaluate their independent association with 
mortality among patlents with stable HF. 
Methods: 548 patients I” the Digitalis investigation Group trial who participated in a 
6MWT were grouped by performance: unable to walk, <300m, 300m-374m, and _> 375m. 
We compared crude all-cause mortaltty (mean follow-up 37 months) across the 6MWT 
groups. MultivarIable Cox proporttonal hazards analyses were performed adlustIng for 
age, sex, ejectlon fraction, functlonal class, creatinine. diabetes, S3, and pulmonary con- 
gestion to ass??& the independent association of 6MWT groups and mortality. 
Results: Overall mortality was 26.8% and each successively higher performance group 
had lower crude mortality (P=O.O02 for trend). In multivarlable analysis, however, the risk 
of death was comparable among patients who were unable to walk, walked c300m, and 
walked 300m-374m. Patients who walked X375m were at lower risk of morlaltty com- 
pared with others. 
Unable to <300m 300s374m 2375m 
Walk (n&l) (n=155) (Il=166) (n=173) 
Crude Mortality 40.7% 29.7% 27.7% 19.7% 
Adjusted Mortality 1.05 0.93 1 .oo 0.71 
HR (95% Cl) (0.61, 1.81) (0.59, 1.45) (Reference) (0.45, 1.12) 
before D4i6 before D4/5 before D4/5 
GT GT GT 
26.5kO.8 30.5eO.7 25.7kO.5 23.551. 26.9il.l 25.1&o. 
+§ 1 9 
4.5kO.2 5.8*0.2+ 4.6i0.i 3.8tO.3 4.620.2 3.9+0.2 
8 
D4l5 D4i!i D4l5 
391 +13 357+17 387+24 
LV PSP (mmHg) 
LV dP/dtmax 
(mmHg/s) 
96.5k6.1 # 78.5k4.6 71.2i5.2 
5x812*784 5 3,285+398 3.000*350 
LV dP/dtmin (mmHg/ -5,275+430 5 -3,294+397 -2.953*396 
s) 
Tau (ms) 9.7*0.7 # 14.2zt1.4 13.8eO.9 
FS: fractional shortening; VCF: velocity of circumferential fiber shortening; HR: heart 
rate; LV PSP: LV peak systolic pressure; LV dP/dtmax, LV dP/dtmin: maximum. mini- 
mum derivative of LV pressure; Tau: time constant of isovolumic LV relaxation; + p<O.Oi 
vs. before GT; #pcO.O5 vs. ShamlLacZ (D415); §p<O.Oi vs. ShamlLacZ (D4/5). 
Conclusion: In viva gene transfer of contractilin produces short-term improvement of LV 
function and enhanced myocardial contractility in the failing CM hamster heart. 
4:15 p.m. 
864-2 Effects of Gene Transfer of Urokinase-Type 
Plasminogen Activator on Extracellular Matrix and 
Ventricular Remodeling in Swine 
Hiroshi Ashlkaaa, Michael Barr, Leslie J. Hsu. Thomas Dieterle. Masahiko Hoshijima, 
John Ross, Jr., Kenneth R. Chien, James W. Covell, Francisco J. Villarreal, University of 
Conclusions: Although crude mortality rates varied by 6MVVT performance, the associa- California, San Diego, La Jolla, CA 
tion between 6MWT and mortakty was mostly attributable to other risk factors. The 
6MWT could not further stratify prognosis among patients with lkmited exercise capacity Background: Ventricular remodelling in the failing heart is a complex process Involving 
who walked less than 375m. a multitude of molecular and cellular events. Matrix metalloproteinases, which induce 
extracellular matrix degradation, are implicated in ventricular remodelling, because inhi- 
bitlon of matrix metalloproteinases attenuates progressive ventricular dilatation. Utilizing 
urokinase plasminogen activator @PA), a protease that initiates a known cascade lead- 
Ing to activation of matrix metalloproteinases , we investigated whether induction of local 
extracellular matrix degradation leads to altered ventricular remodeling. 
Methods: Adenovirus containing human UPA gene (n=3, 3.5~10’~ virus particles (VP)) or 
bgalactosidase gene @=I, 1.4~10’~ vp) was injected into the left antenor descending 
(LAD) branch of the coronary artery of pigs while both the LAD and the great cardiac vein 
are occluded. Local ventricular remodelling was assessed by comparlng changes in end- 
diastolic confIguratIons of transmural arrays of radiopaque markers prior to, and i-2 
weeks post gene transfer. Remodelling deformation was expressed as El l:circumferen- 
teal, EPP:longitud!nal, E33:radlal strains, and E12, E23, El3 transverse shear strains. 
lmmunohistochemistry was performed to detect UPA and type I collagen in the speci- 
mens from both the LAD and left circumflex (LCx) distribution. 
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Results: Assessment of remodelling deformation in the LAD distribution (n=Z) revealed 
an increase in wall thickness (E33=0.14. 0.16) and the range of transverse shears (E13. 
E23) from 4.02 to ~0.1. resulting in net increase in tissue volume (product of stretch 
ratios: 1.21, 1.04). lmmunohistochemistry revealed evidence of UPA transfection in the 
LAD distribution (n=i), and an increase in type I collagen degradation in the LAD distrfbu- 
tion, compared with the LCx distribution (n=2). No increase in type I collagen degradation 
was observed in both the LAD and LCx distribution of the pig in which )?-galactosidase 
gene was delivered (n=l). 
Conclusion: Results from this ongoing study indicate that UPA induces extracellular 
matrix degradation, yielding altered ventricular remodelling. 
4:30 p.m. 
864-3 Reduction of Secondary Vasospasm Limits 
Cardiomyopathy Progression 
Matthew T. Wheeler, Keith A. Collins, Claudia E. Korcarz, Andrew A. Hack, Sara 
Zarnegar, Matthew Lyons, Elizabeth M. McNally, University of Chicago, Chicago, IL 
Background: In humans and mice, sarcoglycan gene mutations cause cardiomyopathy 
and muscular dystrophy characterized by focal cardiac necrosis, cardiomyopathy and 
vasospasm. Mice engineered to lack y-sarcoglycan show evidence of cardiomyopathy, 
but the contribution of vasospasm to this pathology is unknown. 
Methods: Smooth muscle tissues of ysarcoglycan mutant mice were studied by immun- 
ofluorascence and immunoblotting. Microvascular filling was used to evaluate vasos- 
pasm. ysarcoglycan mutant mice (n=lO) were treated with oral verapamil at 1 mg/kgiday 
for 5 months. Treated and untreated ysarcoglycan mutant mice were compared by tran- 
sthoracic echocardiography, ambulatory telemetry. histopathotogy, and microvascular 
filling analysis. 
Results: Microvascular filling of psarcoglycan mutant mice showed focal stenoses con- 
sistent with vasospasm. yet the sarcoglycan complex was not perturbed in vascular 
smooth muscle in ysarcoglycan mutant mice. These data indicate that vasospasm 
develops as a secondary consequence of intrinsic cardiomyocyte degeneration. Vera- 
pamil treatment to reduce secondary vasospasm in ysarcoglycan mutant mice attenu- 
ated mywardial fibrosis. Membrane permeability defects were present but reduced in 
verapamil-treated hearts. Verapamil-treated y-sarcoglycan mice had improved lefl ven- 
tricular fractional shortening (44.3% treated vs. 37.4% untreated), improved maximal 
velocity at the aortic outflow tract (114.9 vs. 92.6 cm/s. ~~0.05) and improved cardiac 
index (1.06 vs. 0.67 mllminig, p<O.OOl) compared to untreated mice. 
Conclusions: These data indicate that secondary, not primary, vasospasm contributes 
to cardiomyopathy progression in sarcoglycan gene mutations. Moreover, verapamil can 
reduce secondary vasospasm and limit the progression of cardiomyopathy. 
4:45 p.m. 
864-4 External Pharmacological Control of Vector-Based 
Phospholamban-Antisense-RNA Expression for the 
Flexible Modulation of Cardiac Calcium Homeostasis 
Wolfaana C. Poller, Henry Fechner, Xiaomin Wang, Dick Dekkers, Jos Lamer% 
University Hospital Benjamin Franklin, Berlin, Germany, Erasmus Universiteit Rotterdam, 
Rotterdam, The Netherlands 
Background: Impaired sarcoplasmic reticulum Ca2+ pump (SERCAP) activrty plays an 
important role in the development of diastolic dysfunction of the failing heart. Genetic 
complementation experiments in MLP-I- x PL-/- knock out mice, and other data, suggest 
that the expression ratlo of PL to SERCAP may be a target for the improvement of dias- 
tolic dysfunction in the failing heart. Previously we have developed PL-antisense-RNA 
strategies using either a consfitutive CMV or an endothelin-l-inducible ANF promoter. 
External control of applied vectors in viva can not be achieved using these systems. We 
report here on the application of a tetracycline (Tat)-inducible promotor to create vectors 
allowing “exogenous activation” by a drug. Methods and Results: In order to reduce 
background activation of the transgenes. PL-antisense-RNA (Plas) and PL-sense-mRNA 
(PLs) used as control, respectively, were cloned downstream of a Tetracyclin Response 
Element (TRE) in a first vector (AdSTRE-PLas). A second vector (Ads-rtTA) expresses a 
reverse tetracyclin Transactivator (rtTA). Analogous two-vector systems were developed 
for luciferase (Luc). The Tat-systems were compared to standard CMV vectors in neona- 
tal rat cardiomyocytes (CMCs). PL in CMCs, CaZ+ uptake activity in CMC homogenates, 
and Ca2+ transients in intact CM&, were measured using standard methods, Luc activ- 
ity by luminometry. More than 65 % of CMCs were routinely expressing both TRE-trans- 
gene and rtTA vector. In the TRE-Luc system, basal transgene activity in the absence of 
Tet was not significantly above the background, whereas at 4OQ nglml Tet, Luc activity 
was 46 % above that of the CMV vector. Under maximal stimulation, the TRE-PLas vec- 
tor had simtlar effects as the CMV-Plas vector upon dose-and time-dependent reduction 
of PL-mRNA and protein, Ca2+ uptake activity, and Ca2+ transients. Both TRE-PLs vec- 
tor and TRE-Plas without Tet had no significant effects. Conclusions: Pharmacological 
control of vector-based PL-antisense-RNA expression may become a more flexible gene 
therapy approach to the improvement of diastolic dysfunction than the previously used 
CMV and ANF promotor vectors, allowing rapid adaptation to the hemodynamic situation. 
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674-l Relation Between Changes in Ejection Fraction Over 
Time and Subsequent Mortality and Morbidity in Val- 
HeFf 
lnderiit S. Anand, Maylene Wang. Riberto Latini, Lloyd Fisher, Yann Tong Chiang, Jay N. 
Cohn, on behalf of the Val-HeFT Investigators, VA Medical Center and University of 
Minnesota, Minneapolis, MN, lstituto di Ricerche Farmacologiche “Mario Negri”, Mitano. 
Italy 
Background: Left ventricular remodeling is considered an important determinant of pro- 
gression of heart failure (HF), and ejection fraction (EF) has consistently been shown to 
predict mortality and morbidity (M&M). Whether changes in EF over time correspond to 
subsequent changes in M&M has not been studied. Such a relationship would further 
strengthen the role of LV remodeling as a surrogate for events. Val-HeFT evaluated the 
efficacy of the ARB valsartan in patients with moderate and severe HF and measured EF 
in over 5000 patients at baseline and over 4500 patients during follow-up, and provided 
data for this study. Methods: Change in echocardiographically derived EF from baseline 
(BL) to 4, 12, and 24 months were analyzed in subgroups by quartiles for subsequent 
M&M. Risk ratio (RR) and 95% Cl were calculated for M&M in all patrents, irrespective of 
treatment using Cox regression, adjusting for baseline EF. Results: BL EF in quartrles 
showed a significant quartile-dependent increase in M&M risk (data not shown). 
Changes in EF from BL to 4 months also showed a signrficant and corresponding change 
in M&M. As compared with patients who had no or little change in EF over time (quartile 
2) patients whose EF decreased (quartile 1) showed a srgnificant increase in RR for 
M&M, whereas patients with an increase in EF (quartiles 3 & 4) showed a decrease in 
RR for M&M. Similar findings were seen for changes in EF at 12 and 24 months. Conclu- 
sions: These data further reinforce the role of EF as a significant surrogate marker in HF. 
6:45 a.m. 
874-2 Hemodynamic Mechanisms of Ejection Fraction 
Improvement With Chronic Carvedilol Treatment in 
Heart Failure: Insights From Three-Dimensional 
Echocardiography 
Mathew S. Maurer, Daniel Burkhoff, Lyna El-Khoury Coffin, Donald L. King, Norma 
Medina. Madeline Yushak. Jonathan D. Sackner-Bernstein. Columbia Universitv. New 
York, NY, St. Luke’sRoosevelt Hospital, New York, NY 
Background. CarvedrIo is known to improve ejection fraction in patients wth CHF but the 
relative contributions of heart rate reduction, afterload reduction and positive inotropism 
to this beneficial effect are unknown. 
Methods. 32 patients (64+12 years old, 20 wth idiopathic and 12 with ischemic cardi- 
omyopathy) with NYHA II-111 underwent serial three dimensional echocardiogram (3DE) 
at baseline and 4 months after initiation of carvedilol. 3DE derived measures of LV vol- 
umes and mass were coupled with sphygmomanometic measurements of arterial pres- 
sures yielding estimates of chamber contractility (end-systolic pressure-volume ratio, 
Res, where PesSBP’O.S), effective arterial elastance (Ea, -TPR’GO/HR) and ventricular 
vascular coupling (EefRes). 
Results. EF increased by 6 f 6 percentage points (from 26+6% to 32*9%, p<O.OOOl). 
The change in EF was correlated with changes in stroke volume (w0.66. p<O.OOOl) but 
not wth changes in end diastolic volume (r=.09, p=NS). Pressure-volume based analysis 
show that Res increased from 0.72*0.39 to 0.60+0.36 mmHg/ml (p=O.O3). Ea decreased 
from 2.liO.6 to 1.7kO.5 mmHg/ml (pcO.001). which was due to a significant decrease in 
HR (from 63+11 to 65+6 bpm, p<O.OOl) with no significant change in TPR (1.3kO.4 vs 
1.3iO.4 ml/mmHglmin). Ea/Res improved from 3.4&1.5 to 2.5il.3 (pcO.001). 
Conclusions: Improved chamber contractility (indexed by increased Res) and decreased 
